Welcome to our dedicated page for Lantheus Holding news (Ticker: LNTH), a resource for investors and traders seeking the latest updates and insights on Lantheus Holding stock.
Lantheus Holdings, Inc. reports news on its radiopharmaceutical business, including diagnostic imaging agents, radiotherapeutic assets, regulatory decisions and financial results. The company organizes revenue around Radiopharmaceutical Oncology, Precision Diagnostics and Strategic Partnerships and Other Revenue, with products used by hospitals, independent imaging centers, government facilities and distribution partners in the United States and abroad.
Recurring updates include quarterly earnings, business guidance, FDA activity for products such as PYLARIFY TruVu, PYLARIFY, Lutetium Lu 177 Dotatate (PNT2003) and LNTH-2501, share repurchases, investor presentations and strategic updates involving radiodiagnostics and radiotherapeutic programs.
Lantheus Holdings (NASDAQ: LNTH) has announced a definitive agreement to sell its SPECT business to SHINE Technologies. The transaction includes the sale of diagnostic agents TechneLite®, NEUROLITE®, Xenon Xe-133 Gas, and Cardiolite®, along with related manufacturing facilities in North Billerica, Massachusetts, and Canadian operations. The deal allows Lantheus to focus on its innovative PET radiodiagnostics and microbubbles portfolio while advancing its radiopharmaceutical pipeline.
The transaction terms include an upfront cash payment, a note convertible into SHINE preferred stock, and potential earnout milestones. This strategic move follows Lantheus' recent agreements to acquire Life Molecular Imaging and Evergreen Theragnostics. The deal is expected to close by year-end, subject to customary conditions.
Lantheus Holdings announced positive results for its Alzheimer's disease radiodiagnostic MK-6240, which successfully met co-primary endpoints in two pivotal studies. The F18-labeled tau PET radiodiagnostic demonstrated strong sensitivity and specificity in detecting tau pathology, a key marker of Alzheimer's disease.
The company plans to submit a New Drug Application (NDA) to the FDA in Q3 2025. MK-6240 targets aggregated tau protein in neurofibrillary tangles and complements Lantheus' existing beta amyloid PET imaging agent, NAV-4694, currently in Phase 3 development.
Market projections indicate the U.S. Alzheimer's Disease radiodiagnostic market could reach over 400,000 scans and $1.5 billion by 2030, driven by increasing disease prevalence, expanded treatment options, and broader PET imaging guidelines. Over 100 therapies targeting beta amyloid or tau are currently in clinical development.
Lantheus Holdings (NASDAQ: LNTH) has scheduled its first quarter 2025 earnings conference call and webcast for May 7, 2025, at 8:00 a.m. ET. The company will discuss its financial and operating results during this presentation.
Participants interested in joining the conference call or webcast can register through the investor relations website at https://investor.lantheus.com/news-events/calendar-of-events. Registration is recommended 15 minutes before the event to avoid delays. A replay will be made available approximately two hours after the webcast concludes and will remain accessible for at least 30 days on the same webpage.
Lantheus Holdings (NASDAQ: LNTH) has completed its acquisition of Evergreen Theragnostics, a clinical-stage radiopharmaceutical company, as announced on January 28, 2025. The acquisition brings key assets to Lantheus including:
- OCTEVY™, a registrational-stage PET diagnostic imaging agent for neuroendocrine tumors, complementing Lantheus' therapeutic candidate PNT2003
- A portfolio of clinical and pre-clinical theranostic pairs
- Radioligand therapy manufacturing infrastructure
- A revenue-generating CDMO business
The strategic move strengthens Lantheus' position in the radiopharmaceutical sector by expanding its capabilities across development, manufacturing, and commercialization.
Lantheus Holdings (NASDAQ: LNTH) reported strong financial results for Q4 and full year 2024. The company achieved worldwide revenue of $391.1M in Q4 (+10.5% YoY) and $1.53B for full year 2024. PYLARIFY reached blockbuster status with over $1B in net sales, while Q4 sales grew 15.7% to $266.0M.
Q4 highlights include DEFINITY sales increase of 17.9% to $86.2M, operating income decrease of 17.2% to $113.9M, and adjusted EPS decline of 9% to $1.59. The company's cash position strengthened to $912.8M by year-end 2024.
Lantheus announced strategic acquisitions including Life Molecular Imaging and Evergreen Theragnostics, expected to close in H2 2025. These deals aim to expand the company's radiopharmaceutical portfolio and manufacturing capabilities. The company also initiated a $250M share repurchase program, with $100M already executed at an average price of $89.59.
Lantheus Holdings (NASDAQ: LNTH), a leading radiopharmaceutical company, has announced its participation in three major upcoming investor conferences in February and March 2025. The company's management team will present at:
- B. Riley Securities Precision Oncology & Radiopharma Day in New York (February 28)
- TD Cowen 45th Annual Health Care Conference in Boston (March 4, 2:30 PM ET)
- Leerink Global Healthcare Conference 2025 in Miami (March 11, 1:40 PM ET)
Live webcasts will be available for the TD Cowen and Leerink conferences through the Investors section of Lantheus's website. Replay access will be maintained for at least 30 days following the presentations.
Lantheus Holdings (NASDAQ: LNTH) has announced it will host a conference call and webcast to discuss its Q4 and full year 2024 financial results on Wednesday, February 26, 2025, at 8:00 a.m. ET.
Participants are encouraged to register fifteen minutes before the scheduled start time through the company's investor relations website to avoid delays. A replay of the webcast will be available approximately two hours after the event and will remain accessible for at least 30 days on the same web page.
Lantheus Holdings (NASDAQ: LNTH) has announced upcoming presentations of piflufolastat F 18 (PYLARIFY) data at the 2025 ASCO Genitourinary Cancers Symposium in San Francisco. Two key presentations will showcase PYLARIFY's capabilities: one focusing on early detection of recurrent prostate cancer in patients with minimal PSA levels, and another examining PYLARIFY's role in newly-diagnosed and recurrent prostate cancer patients based on registry data.
The presentations are scheduled for February 13, 2025, during Poster Session A, with studies from the University of California's Department of Radiation Oncology and Carolina Urologic Research Center. The research highlights PYLARIFY's effectiveness in real-world applications and its ability to detect prostate cancer recurrence in low PSA cases.